SUPPLEMENTARY MATERIAL

A Maximum Use Trial of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Robert Bissonnette, MD, FRCPC,1 Robert S. Call, MD,2 Tooraj Raoof, MD,3 Zhaoyin Zhu, PhD,4 Swamy Yeleswaram, PhD,4 Xiaohua Gong, PhD,4 Mark Lee, MD5

1Innovaderm Research, Montreal, QC, Canada; 2Clinical Research Partners, Richmond, VA, USA; 3Encino Research Center, Encino, CA, USA; 4Incyte Corporation, Wilmington, DE, USA; 5Progressive Clinical Research, San Antonio, TX, USA

American Journal of Clinical Dermatology
Corresponding author: Robert Bissonnette, MD (rbissonnette@innovaderm.com)

Contents

Table of Contents
Table S1. Platelet and Hemoglobin Levels in the 5 Patients With Highest Css ........... 2

Figure S1. Mean Plasma Concentrations on Day 1 and Day 28 in the (A and D) Overall Population and by (B and E) Baseline BSA and (C and F) Age Groups ......................... 3

Figure S2. IGA Scores by Study Day ................................................................. 4

Figure S3. Change From Baseline in Daily Itch NRS Score .................................. 5

Figure S4. Proportion of Patients Achieving EASI-75 ........................................ 6

Figure S5. Representative Clinical Images.......................................................... 7
Table S1. Platelet and Hemoglobin Levels in the 5 Patients With Highest $C_{ss}$

| Age, y/Sex | BSA Treated, % | $C_{ss}$, nM | Platelet Count on Day 28, $10^9$/L | Change From Baseline | Hemoglobin on Day 28, g/L | Change From Baseline |
|------------|----------------|--------------|-----------------------------------|----------------------|---------------------------|-----------------------|
| 45/M       | 25             | 111          | 307                               | 9                    | 135                       | −4                    |
| 46/M       | 27             | 122          | 243                               | 27                   | 180                       | −2                    |
| 13/M       | 43.4           | 269          | 345                               | 81                   | 164                       | 10                    |
| 32/F       | 45             | 711          | 449                               | 137                  | 130                       | −15                   |
| 60/M       | 90             | 1870         | 173                               | −227                 | 136                       | −18                   |

BSA, body surface area; $C_{ss}$, steady-state plasma concentration.
Figure S1. Mean Plasma Concentrations on Day 1 and Day 28 in the (A and D) Overall Population and by (B and E) Baseline BSA and (C and F) Age Groups

Data are shown as semilog plots.
Error bars represent standard error of the mean.
BSA, body surface area.
Figure S2. IGA Scores by Study Day

IGA, Investigator's Global Assessment.
Figure S3. Change From Baseline in Daily Itch NRS Score

NRS, numerical rating scale.
Figure S4. Proportion of Patients Achieving EASI-75

EASI-75, ≥75% improvement in Eczema Area and Severity Index.
Figure S5. Representative Clinical Images